Rudd C E, Schneider H
Division of Tumor Immunology, Department of Cancer Immunology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 02115, USA.
Curr Biol. 2000 May 4;10(9):R344-7. doi: 10.1016/s0960-9822(00)00463-2.
Cbl, a negative regulator of immune signaling, has recently been shown to act as a ubiquitin-protein ligase. Further, two new papers describing Cbl-b-deficient mice suggest that Cbl-b sets the threshold of signaling in T and B cells and prevents the development of autoimmunity.
Cbl是免疫信号的负调节因子，最近已被证明可作为一种泛素蛋白连接酶。此外，两篇描述Cbl - b缺陷小鼠的新论文表明，Cbl - b设定了T细胞和B细胞信号传导的阈值，并可预防自身免疫的发生。
